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Here we report the case of an 18-year-old woman with chronic myeloid leukemia (CML) who became pregnant while undergoing
treatment with dasatinib. Before pregnancy, she received imatinib mesylate therapy but could not tolerate the treatment. The
regimenwasthenchangedtodasatinibatadoseof70mgb.i.d.Whileshewasinhematologicalremissionandondasatinibtherapy,
she became pregnant. The unplanned pregnancy was identiﬁed after the patient had experienced four weeks of amenorrhea.
Becausethepatientelectedtocontinuethepregnancytoterm,dasatinibwasstoppedimmediately.Meanwhile,CMLhematological
relapse occurred and then she was treated with interferon-α (IFN-α) (9 million IU/day) throughout the pregnancy without a
complete hematological response. She successfully gave birth to a male baby at 33 weeks by cesarean section delivery with no
sequelae or malformations. Although this experience is limited to a single patient, it provides a useful contribution for counselling
patients inadvertently exposed to dasatinib during pregnancy.
1.Introduction
CML is a myeloproliferative disorder of blood stem cells
[1]. The causative molecular defect is the bcr-abl protein,
which is encoded by the Philadelphia chromosome (Ph) [2].
This genetic anomaly arises from an exchange of genetic
materialbetweenchromosomes9and22,whichresultsinthe
fusion of the breakpoint cluster region (bcr) and the Abelson
leukemia virus (abl) genes. The resulting gene encodes a
constitutively active protein kinase that activates a number
of proteins involved in cell-cycle regulation that hasten cell
division and aﬀect DNA repair. A new class of medications
known as TKIs has been developed to selectively inhibit
the activity of this abnormal enzyme. Imatinib mesylate
is a TKI able to produce long-term suppression of CML
in the majority of patients [3]. The drug has become a
ﬁrst-line therapy for newly diagnosed CML patients. As a
result, female patients with CML who are of childbearing
age and are currently being treated with imatinib now
ﬁnd themselves contemplating reproductive opportunities
that would not have otherwise been possible. However, the
advantages of this therapy in women of reproductive age
are balanced by concerns of imatinib increasing the risk
of birth defects. Dasatinib is an oral TKI that binds to
active and inactive forms of bcr-abl kinase. It is licensed for
the treatment of adults with chronic, accelerated, or blast-
phase CML with resistance or intolerance to prior therapy,
includingimatinib.However,thesafetyproﬁleofinadvertent
exposure to this drug in pregnancy is still in question. Here
we describe a normal pregnancy outcome in a case of ﬁrst-
trimester exposure to dasatinib in an 18-year-old pregnant
woman with CML.
2.CaseReport
In January 2001, an 18-year-old woman was diagnosed
with Ph+ CML in the chronic phase at another hospital.
She had been given IFN-α 6 × 106 U/day before present-
ing to our hospital for treatment of CML. Three years2 Advances in Hematology
after the diagnosis, she was referred to our hospital for
further workup. On admission, her physical examination
was normal. She was in complete hematological remission,
but without any cytogenetic response. Hematological val-
ues were: hemoglobin 10.2g/dL, platelets 447×109/L, and
white blood cell count 3.69×109/L (60% neutrophils, 3%
eosinophils, 2% basophils, 20% lymphocytes, 2% mono-
cytes, 0% myeloblasts, 8% promyelocytes, 4% myelocytes,
and 1% metamyelocytes). Conventional chromosome band-
ing revealed a 46,XX,t(9;22) karyotype with no other
abnormalities. In March 2004, she was started on imatinib
at 400mg daily after giving-written consent. Five months
later, she developed grade 4 myelotoxicity evidenced by
neutropenia with a neutrophil count of 1 × 109 L. As a
result, treatment with imatinib was temporary discontinued.
In November 2004, a further attempt with lower-dose
imatinib (300mg daily) combined with granulocyte-colony
stimulating factor (G-CSF) again resulted in neutropenia
(absolute neutrophil count (ANC) < 100). Because of per-
sistent myelotoxicity, imatinib was permanently withdrawn.
In June 2005, after giving an informed consent, she was
enrolled in the START Protocol (BMS 180 034) and was
slated to receive dasatinib at a dose of 70mg b.i.d. At that
time, the diﬀerential peripheral blood count was normal and
85% of the interphase cells were Ph+ by ﬂuorescence in situ
hybridization (FISH) assay. The patient was counseled about
the teratogenic potential of the agent and was advised to
avoid pregnancy while on treatment. After three years of
therapy with dasatinib, the number of Ph+ cells decreased
from 85% to 25%, but she had severe myelotoxicity (grade
4 neutropenia and grade 4 thrombocytopenia). According
to the therapeutic protocols, the dasatinib dose was reduced
to 40mg b.i.d (Figure 1). In July 2008, while she was
in hematological remission and on dasatinib therapy, she
became pregnant. The unplanned pregnancy was identiﬁed
during her ﬁrst trimester of gestation after the patient
had experienced four weeks of amenorrhea. This timing
indicated that the fetus was inadvertently exposed to the
dasatinib. The patient was informed of the potential fetal
toxicities of the therapy. After detailed counseling, the
patient elected to continue her pregnancy, and dasatinib
was stopped immediately. Meanwhile, CML hematological
relapse occurred and the F317L mutation in bcr-abl was
detected. Because of hematological relapse, she was treated
with IFN (9 million IU/day) and maintained on the same
dose during her pregnancy without complete hematological
response. A follow-up with ultrasound scans throughout
the course of the pregnancy was unremarkable. In February
2009, she delivered via cesarean section a healthy male
baby weighing 2.1kg with an Apgar score of 9 at ten
minutes at gestational week 33. Despite the low birth weight,
the infant’s growth and development have been normal
through 8 months of age without any evidence of congenital
malformations. Hydroxyurea therapy at a dose of 1.5g/day
was reinstituted after a few days of delivery and continued
for four months. Dasatinib was the only second generation
TKI available at that time, and it was reintroduced at
the dose of 100mg/day. Currently, she is in a complete
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Figure 1: Molecular responses during the entire observation
period.
a major molecular response. The patient has been now put
on nilotinib therapy.
3. Discussion
CML disease in pregnancy is a rare condition, with an
annual incidence of 1 per 100,000 pregnancies [4]. The
disease during pregnancy has been traditionally managed
conservatively by leukapheresis [5, 6], hydroxyurea [7, 8]
and interferon [9–11] because it has an initial chronic phase
that may not require an immediate therapy and pregnancy
per se does not aﬀect CML. The therapeutic management
of CML in pregnant women with targeted therapies often
poses substantial challenges to both patients and their
physicians. The main concern is whether to stay on these
agents, which carry the risks of birth defects, or stop the
medications and risk relapse. The eﬃcacy and safety of
molecular target therapies during conception have not been
adequately evaluated. This pitfall is attributed mainly to
the rarity of CML in young women and the exclusion of
pregnant women from active trials. In general, molecular
targeted therapies are not recommended during conception
because of concerns raised by animal experiments that have
suggested an embryotoxic eﬀect of these agents [12–14].
However, it remains uncertain how these eﬀects apply to
humans. Currently, much literature exists regarding the
evaluation of the outcome of pregnancy while on imatinib
and most cases have involved successful pregnancies after
the drug is withdrawn. One of the most comprehensive
data sets on the eﬀect of imatinib on pregnancy was
recently reported by Pye et al. [15]. In Pye et al’s. study,
imatinib was evaluated in 180 women who were exposed
to treatment during pregnancy; outcomes were available for
125 patients. In total, 50% delivered a healthy baby, 28%
electedtohaveaterminationand14%hadamiscarriage.The
thoroughreviewoftheEnglishlanguageliteratureonwomen
who became pregnant while taking imatinib conducted byAdvances in Hematology 3
Cole et al. [16] identiﬁed a total of 217 reported pregnancy
events. Of these, 171 carried their pregnancy to term, 24
had spontaneous abortions and 62 had unknown outcomes.
Among the 109 pregnancies with the known outcome being
that the patient intended to carry their child to term, 36
(33%) had complications, including spontaneous abortion
in 24 patients, stillbirth in 1 patient, malformations in 9
patients and low birth weight in 2 patients.
Dasatinib is a multi-targeted kinase inhibitor of bcr/abl
and Src kinases that has been developed to overcome
intolerance to prior therapy, including the current frontline
therapy imatinib, and to suppress the activity of imatinib-
resistant bcr-abl mutants [17]. The drug is structurally
unrelated to imatinib and is able to bind and inhibit both
theactiveandinactiveconformationsofabl,resultingin100-
to 300-fold higher activity than imatinib [17, 18]. Although
dasatinib has an excellent eﬃcacy proﬁle, there has been
very limited experience with this agent in women with CML
who become pregnant while on therapy. To date, only one
recent study of the use of dasatinib during early pregnancy
has been reported in a scientiﬁc meeting [19]. Cortes et
al. described the outcomes of pregnancies of 16 patients (8
females and 8 males) who received dasatinib therapy. Of the
eight females who conceived while receiving dasatinib, three
had therapeutic abortions (two due to patient decision, one
for unknown reasons), two had spontaneous abortions (one
at eight weeks in a 38-year-old patient [G1P1], one at nine
weeks gestation in a 33-year-old [G3P3] and three delivered
(one normal, one by cesarean and one unknown). Although
none of these women or their neonates experienced serious
adverse outcomes, the authors concluded that women of
reproductive age who have been started on dasatinib should
use eﬀective contraception. There has been only one case
report of the use of nilotinib, a second generation TKI,
during early pregnancy. Conchon et al. [20]d e s c r i b e da3 0 -
year-old mother with CML who became pregnant for the
second time while on nilotinib for 7.4 weeks of gestation
and delivered a male infant who weighed 3.2kg at 33 weeks
without congenital malformations.
To date, our patient is one of the ﬁrst reports of a
successful pregnancy and delivery of a healthy newborn
exposed to dasatinib for approximately eight weeks after
conception, during the key period for embryogenesis (3 to
8 weeks of postconception life). We recognize that similar
exposure to TKIs may be inadequate for patients with more
extensive disease. However, this case and other recent reports
[20–22] show that successful outcomes are possible for
women with chronic phase CML during pregnancy.
Because conception during treatment is not recom-
mended, couples must be counseled on the risks and
beneﬁts of their decision. Although possible serious eﬀects
onfetalorganscannotbedisregardedinwomenwhobecome
pregnant while receiving therapy, physicians should proceed
with caution and closely follow the patients. We believe that
the use of TKIs concomitantly with oral contraceptives is
still prudent pending more methodologically sound studies
involving extensive and adequate clinical data to assess out-
comes of TKI-exposed pregnancies and enable the detection
of any related fetal defects.
References
[1] C. L. Sawyers, “Chronic myeloid leukemia,” The New England
Journal of Medicine, vol. 340, no. 17, pp. 1330–1340, 1999.
[2] S. Faderl, M. Talpaz, Z. Estrov, et al., “The biology of chronic
myeloid leukemia,” The New England Journal of Medicine, vol.
341, no. 3, pp. 164–172, 1999.
[3] S. G. O’Brien, F. Guilhot, R. A. Larson, et al., “Imatinib
compared with interferon and low-dose cytarabine for newly
diagnosed chronic-phase chronic myeloid leukemia,” The New
England Journal of Medicine, vol. 348, no. 11, pp. 994–1004,
2003.
[4] M. Lichtman and J. Liesveld, “Acute myelogenous leukemia,”
in Williams Hematology, E. Beutler, M. Lichtman, B. Coller,
et al., Eds., vol. 1047, McGraw-Hill, New York, NY, USA, 6th
edition, 2001.
[5] M. S. Bazarbashi, M. R. Smith, C. Karanes, I. Zielinski, and
C. R. Bishop, “Successful management of Ph chromosome
chronic myelogenous leukemia with leukapheresis during
pregnancy,”AmericanJournalofHematology,vol.38,no.3,pp.
235–237, 1991.
[6] F. J. Strobl, K. V. Voelkerding, and E. P. Smith, “Management
of chronic myeloid leukemia during pregnancy with leuka-
pheresis,”JournalofClinicalApheresis,vol.14,no.1,pp.42–44,
1999.
[7] M. Celiloglu, S. Altunyurt, and B. Unbar, “Hydroxyurea
treatment for chronic myeloid leukemia during pregnancy,”
Acta Obstetricia et Gynecologica Scandinavica, vol. 79, no. 9,
pp. 803–804, 2000.
[ 8 ]M .P a t e l ,I .A .F .D u k e s ,a n dJ .C .H u l l ,“ U s eo fh y d r o x y u r e a
in chronic myeloid leukemia during pregnancy: a case report,”
American Journal of Obstetrics and Gynecology, vol. 165, no. 3,
pp. 565–566, 1991.
[9] M.R.Baer,H.Ozer,andK.A.Foon,“Interferon-alphatherapy
during pregnancy in chronic myelogenous leukaemia and
hairy cell leukaemia,” British Journal of Haematology, vol. 81,
no. 2, pp. 167–169, 1992.
[10] C. Baykal, N. Zengin, F. Cos ¸kun, et al., “Use of hydroxyurea
and alpha-interferon in chronic myeloid leukemia during
pregnancy: a case report,” European Journal of Gynaecological
Oncology, vol. 21, no. 1, pp. 89–90, 2000.
[11] M. Kuroiwa, H. Gondo, K. Ashida, et al., “Interferon-alpha
therapyforchronicmyelogenousleukemiaduringpregnancy,”
American Journal of Hematology, vol. 59, no. 1, pp. 101–102,
1998.
[12] GLEEVEC (imatinib mesylate) [package Insert]: East
Hanover, 2001.
[13] Tasigna: (nilotinib) [package Insert]: East Hanover NNPC,
2007.
[14] Sprycel [package insert]. Princeton NB-MS, 2007.
[15] S. M. Pye, J. Cortes, P. Ault, et al., “The eﬀects of imatinib on
pregnancy outcome,” Blood, vol. 111, no. 12, pp. 5505–5508,
2008.
[16] S. Cole, H. Kantarjian, P. Ault, et al., “Successful completion of
pregnancyinapatientwithchronicmyeloidleukemiawithout
active intervention: a case report and review of the literature,”
Clinical Lymphoma & Myeloma, vol. 9, no. 4, pp. 324–327,
2009.
[17] N. P. Shah, C. Tran, F. Y. Lee, et al., “Overriding imatinib
resistance with a novel ABL kinase inhibitor,” Science, vol. 305,
no. 5682, pp. 399–401, 2004.4 Advances in Hematology
[18] J. S. Tokarski, J. A. Newitt, C. Y. Chang, et al., “The structure
of Dasatinib (BMS-354825) bound to activated ABL kinase
domain elucidates its inhibitory activity against imatinib-
resistant ABL mutants,” Cancer Research, vol. 66, no. 11, pp.
5790–5797, 2006.
[19] J. Cortes, S. O’Brien, P. Ault, et al., “Pregnancy outcomes
among patients with chronic myeloid leukemia treated with
Dasatinib,” Blood, vol. 112, 2008, Abstract no. 3230.
[20] M. Conchon, S. S. Sanabani, and I. Bendit, “Two successful
pregnancies in a woman with chronic myeloid leukemia
exposed to nilotinib during the ﬁrst trimester of her second
pregnancy: case study,” Journal of Hematology and Oncology,
vol. 42, no. 2, 2009.
[21] P. Ault, H. Kantarjian, S. O’Brien, et al., “Pregnancy among
patientswithchronicmyeloidleukemiatreatedwithimatinib,”
Journal of Clinical Oncology, vol. 24, no. 7, pp. 1204–1208,
2006.
[22] L. Garderet, R. Santacruz, V. Barbu, et al., “Two successful
pregnancies in a chronic myeloid leukemia patient treated
withimatinib,”Haematologica,vol.92,no.1,pp.e9–e10,2007.